Pharmaceuticals

An FDA setback for its new mastitis drug prompts ImmuCell to double down on its profitable calf health franchise, First Defense®, in a major strategic shift.

Swisslog Healthcare appoints Maria Garces from competitor Omnicell as VP, signaling an aggressive push to innovate and dominate the health tech market.

A major acquisition turned sour, a 25% stock crash, and now a class action lawsuit. Inside Perrigo's costly infant formula venture and what it means.

Mirum raises over a quarter-billion dollars to acquire Bluejay Therapeutics, targeting a high-potential liver disease drug and signaling major growth.

A landmark executive order to reschedule cannabis and create a Medicare CBD program could unleash a $30B market and redefine the economics of the industry.

In a landmark deal, BioMarin acquires Amicus Therapeutics, gaining high-growth drugs and reshaping the landscape for patients with rare genetic disorders.

A landmark executive order reclassifying cannabis is set to unleash a wave of biopharma innovation, validating science-first firms like Avicanna.

A cancer research firm is betting its future on Zcash, recruiting the crypto's top minds. Is this the start of institutional adoption for privacy coins?

Alvotech and Teva's settlement with Regeneron for an Eylea biosimilar paves the way for a 2026 launch, promising increased competition and lower costs.

A new settlement positions a cost-effective alternative to the blockbuster eye drug Eylea for a 2026 U.S. launch, signaling intense market disruption.

With backing from AstraZeneca and Pfizer, Beijing’s Syneron Bio is using its AI-driven platform to develop novel drugs for cancer and chronic illness.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.

An executive order accelerates moving cannabis to Schedule III, promising massive tax breaks for businesses but leaving advocates wanting more federal reform.

As pharma sells GLP-1s directly to patients, doctors are split on the new model. Is it a lifeline for access or a risk to integrated patient care?

A simple, low-cost heart pill may hold the key to treating Alzheimer's and kidney disease. CardioPharma is now funding research to unlock its potential.

Millions struggle to swallow pills. Azurity's new FDA-approved liquid hypertension drug, Javadin, offers a ready-to-use solution for better adherence.

The biotech upstart will present a bold pipeline, including a head-to-head trial against a market leader and a first-in-class autoimmune eye disease therapy.

A new pharma-tech alliance aims to leverage quantum computing and AI to create safer opioids, but the non-binding deal faces significant hurdles.

Avantor appoints financial heavyweight Simon Dingemans to its board, a strategic move to accelerate its ambitious turnaround amid market pressures.